Some recently opened trials

ETOP 10-16 BOOSTER (CTRIAL-IE 16-61)

The purpose of the trial is to compare osimertinib and bevacizumab versus osimertinib alone for patients with advanced non-small cell lung cancer

E7080-G000-307 (CTRIAL-IE 16-69)

The main purpose of this trial is to assess the safety and efficacy of the drug lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of participants with advanced renal cell carcinoma.

BMS CA 209-651 (CTRIAL-IE 17-20)
The main purpose of this trial is to compare the effectiveness of nivolumab and ipilimumab with the EXTREME study regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer.

Roche M029872 (CTRIAL-IE 16-15)
The main purpose of this trial is to compare atezolizumab versus single agent chemotherapy in patients who have not yet received any treatment for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who are unsuitable for platinum-containing therapy.

BMS CA 209-9LA (CTRIAL IE 17-23)
A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC).

MErCuRIC1 (CTRIAL-IE 16-58)
The main purpose of this trial is to test a new combination of two drugs, Binimetinib and Crizotinib for treatment of colorectal cancer.

DARS (CTRIAL-IE 16-23)
The aim of the trial is to compare the people having the Do-IMRT with those having standard IMRT treatment for head and neck cancer in or close to the throat

ARMO Artist (CTRIAL-IE 16-77)
This trial aims to compare the effectiveness of a drug called AM0010 in combination with FOLFOX with FOLFOX alone. measured by overall survival, in patients with metastatic pancreatic cancer.

CA017-055 (CTRIAL-IE 17-39)
This trial aims to demonstrate that treatment with IDO1 inhibitor BMS-986205 in combination with nivolumab will have clinical activity in participants with previously untreated, unresectable or metastatic melanoma.